Auricular Vagal Nerve Stimulation for Neuromodulation

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Kristie Coleman, New York, NY
Neuromodulation
Auricular Vagal Nerve Stimulation - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The Non-invasive Vagus Nerve Stimulation in Patients Undergoing Electrophysiological Study is a single center, pilot, prospective study that aims at evaluating the effects of auricular vagus nerve stimulation (aVNS) on the human cardiac conduction system.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Neuromodulation

Study Objectives

15 Primary · 0 Secondary · Reporting Duration: Pre procedure/procedure

Pre procedure/procedure
Change in A-H Interval
Change in AV Node Effective Refractory Period
Change in AV Node Wenckebach Cycle Length
Change in Accessory Pathway Anterograde Effective Refractory Period ERP
Change in Accessory Pathway Retrograde Effective Refractory Period ERP
Change in Atrial Effective Refractory Period
Change in H-V Interval
Change in QRS Duration
Change in QT Duration
Change in Right Ventricular Effective Refractory Period ERP
Change in Sinus Cycle Length
Change in Sinus Node Recovery Time
Change in retrograde block cycle length
Supraventricular Tachycardia Termination
Supraventricular Tachycardia induction

Trial Safety

Safety Progress

1 of 3

Other trials for Neuromodulation

Trial Design

1 Treatment Group

Auricular Vagal Nerve Stimulation
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Auricular Vagal Nerve Stimulation · No Placebo Group · N/A

Auricular Vagal Nerve Stimulation
Device
Experimental Group · 1 Intervention: Auricular Vagal Nerve Stimulation · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: pre procedure/procedure
Closest Location: Kristie Coleman · New York, NY
Photo of New York 1Photo of New York 2Photo of New York 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Neuromodulation
0 CompletedClinical Trials

Who is running the clinical trial?

University of OklahomaOTHER
410 Previous Clinical Trials
95,596 Total Patients Enrolled
Northwell HealthLead Sponsor
409 Previous Clinical Trials
290,200 Total Patients Enrolled
Stavros E Mountantonakis, MDPrincipal InvestigatorNorthwell Health

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.